IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 366 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $24,314,955 | +29.0% | 536,044 | +16.7% | 0.00% | +50.0% |
Q2 2023 | $18,845,858 | -16.7% | 459,319 | -27.4% | 0.00% | 0.0% |
Q1 2023 | $22,610,697 | -6.1% | 632,644 | -0.7% | 0.00% | -33.3% |
Q4 2022 | $24,071,311 | -2.8% | 637,313 | +13.8% | 0.00% | 0.0% |
Q3 2022 | $24,767,000 | +4.0% | 559,956 | -13.0% | 0.00% | 0.0% |
Q2 2022 | $23,824,000 | -19.3% | 643,552 | -19.3% | 0.00% | 0.0% |
Q1 2022 | $29,526,000 | +58.3% | 797,158 | +30.1% | 0.00% | +50.0% |
Q4 2021 | $18,648,000 | -21.7% | 612,835 | -13.7% | 0.00% | 0.0% |
Q3 2021 | $23,816,000 | -16.8% | 710,117 | -1.0% | 0.00% | -33.3% |
Q2 2021 | $28,622,000 | -12.2% | 717,497 | -1.0% | 0.00% | 0.0% |
Q1 2021 | $32,594,000 | -7.3% | 724,983 | +16.6% | 0.00% | -40.0% |
Q4 2020 | $35,170,000 | -13.5% | 622,014 | -27.4% | 0.01% | -16.7% |
Q3 2020 | $40,656,000 | -6.8% | 856,822 | +15.8% | 0.01% | -14.3% |
Q2 2020 | $43,629,000 | +23.8% | 740,005 | -0.7% | 0.01% | +16.7% |
Q1 2020 | $35,251,000 | -23.8% | 745,575 | -2.6% | 0.01% | -14.3% |
Q4 2019 | $46,248,000 | -7.0% | 765,573 | -7.8% | 0.01% | 0.0% |
Q3 2019 | $49,753,000 | -18.1% | 830,460 | -12.2% | 0.01% | -22.2% |
Q2 2019 | $60,778,000 | +0.0% | 945,685 | +26.3% | 0.01% | 0.0% |
Q1 2019 | $60,759,000 | -10.4% | 748,544 | -40.3% | 0.01% | -25.0% |
Q4 2018 | $67,801,000 | +73.1% | 1,254,158 | +65.2% | 0.01% | +100.0% |
Q3 2018 | $39,160,000 | +4.8% | 759,214 | -15.3% | 0.01% | 0.0% |
Q2 2018 | $37,367,000 | +0.5% | 896,746 | +6.3% | 0.01% | 0.0% |
Q1 2018 | $37,171,000 | -11.6% | 843,243 | +0.9% | 0.01% | -14.3% |
Q4 2017 | $42,027,000 | -41.4% | 835,509 | -41.0% | 0.01% | -36.4% |
Q3 2017 | $71,745,000 | +58.8% | 1,415,090 | +59.3% | 0.01% | +22.2% |
Q2 2017 | $45,178,000 | +24.8% | 888,096 | -1.4% | 0.01% | +28.6% |
Q1 2017 | $36,198,000 | -18.9% | 900,447 | -3.5% | 0.01% | -30.0% |
Q4 2016 | $44,639,000 | +83.0% | 933,295 | +40.2% | 0.01% | +100.0% |
Q3 2016 | $24,394,000 | +51.1% | 665,765 | -4.0% | 0.01% | +25.0% |
Q2 2016 | $16,145,000 | -60.0% | 693,220 | -30.4% | 0.00% | -60.0% |
Q1 2016 | $40,341,000 | -16.1% | 996,078 | +28.4% | 0.01% | -9.1% |
Q4 2015 | $48,057,000 | – | 776,007 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |